$SPRO News

GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs

Spero Shares Jump After FDA Clears First Oral Carbapenem Antibiotic for U.S. Market (SPRO)

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

Spero Therapeutics: Approval Upside, Commercial Friction (Initiating Hold)

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

Spero Therapeutics Q1 EPS $(0.13) Beats $(0.18) Estimate, Sales $258.000K Down From $5.874M YoY

Uncovering 3 Penny Stocks With Market Caps Under $700M

Spero Therapeutics Inc (NASDAQ:SPRO) Reports Q4 Earnings Beat and Positive Regulatory Step

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

Spero Therapeutics Q4 EPS $0.53 Beats $(0.40) Estimate, Sales $41.297M Up From $15.044M YoY

Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update

Spero Therapeutics Q3 EPS $(0.13) Beats $(0.39) Estimate, Sales $5.442M Down From $13.469M YoY

Insights Ahead: Spero Therapeutics's Quarterly Earnings

Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025

Spero Therapeutics, Inc. (SPRO) Presents at IDWeek 2025 - Slideshow